MacroGenics, Inc.
MGNX Healthcare Biotechnology
In the quarter to June 2026, revenue grew 378.0%, EPS grew 154.4% and free cash flow grew 12.9%, each against the same quarter a year earlier.
Follow MGNX
MacroGenics, Inc. (MGNX) EV/Sales
As of 16 October 2026, MacroGenics, Inc. (MGNX) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −0.8× (March 2025) to 52.4× (November 2017); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.5× | — |
| FY2024 | 0.1× | (99.21%) |
| FY2023 | 6.9× | 333.66% |
| FY2022 | 1.6× | (82.93%) |
| FY2021 | 9.4× | 5.25% |
| FY2020 | 8.9× | 81.92% |
| FY2019 | 4.9× | 0.21% |
| FY2018 | 4.9× | 91.29% |
| FY2017 | 2.5× | (43.79%) |
| FY2016 | 4.5× | (29.85%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | 206.68% |
| Mar 2026 | 0.2× | — |
| Dec 2025 | −0.5× | — |
| Sep 2025 | −0.3× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IFRX InflaRx N.V. compare | −1,061× |
| KROS Keros Therapeutics, Inc. compare | −1.4× |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| MGNX MacroGenics, Inc. | 0.2× |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| ALEC Alector, Inc. compare | 3.6× |
| CAMP CAMP4 Therapeutics Corporation compare | 22.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)